Content area

|
|

Autolog stamcellebehandling til patienter med multipel sklerose

Forfatter(e)
Freja Jespersen1, Anne Fischer-Nielsen2, Søren Lykke Petersen3 & Morten Blinkenberg1
1) Dansk Multipel Sclerose Center, Rigshospitalet 2) Stamcellesektionen, Blodbanken, Rigshospitalet 3) Klinik for Blodsygdomme, Rigshospitalet

Ugeskr Læger 2019;181:V03190186
Reference: 
Ugeskr Læger 2019;181:V03190186

Freja Jespersen, Anne Fischer-Nielsen, Søren Lykke Petersen & Morten Blinkenberg:

Autologous haematopoietic stem cell transplantation of patients with multiple sclerosis

Ugeskr Læger 2019;181:V03190186

Immunosuppression with chemotherapy followed by autologous haematopoietic stem cell transplantation has proven to be an effective long-term treatment for younger patients with relapsing-remitting multiple sclerosis and clinical as well as radiological evidence of high disease activity. The conditioning regimen can be of either high, intermediate or low intensity. Due to the safety profile and favourable efficacy measures, the low intensity regimen cyclophosphamide + anti-thymocyte globulin is currently used in Denmark as standard regimen.

Du skal være logget ind for at læse denne artikel
Log ind

Right side